nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—XDH—Azathioprine—systemic scleroderma	0.193	0.455	CbGbCtD
Carvedilol—CYP1A2—Pentoxifylline—systemic scleroderma	0.0348	0.082	CbGbCtD
Carvedilol—CYP1A2—Leflunomide—systemic scleroderma	0.0332	0.0782	CbGbCtD
Carvedilol—ABCB1—Lisinopril—systemic scleroderma	0.0304	0.0717	CbGbCtD
Carvedilol—CYP2C9—Leflunomide—systemic scleroderma	0.0299	0.0705	CbGbCtD
Carvedilol—ABCB1—Captopril—systemic scleroderma	0.0228	0.0537	CbGbCtD
Carvedilol—CYP2D6—Captopril—systemic scleroderma	0.0215	0.0506	CbGbCtD
Carvedilol—NPPB—pulmonary artery—systemic scleroderma	0.0202	0.125	CbGeAlD
Carvedilol—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0179	0.0422	CbGbCtD
Carvedilol—ABCB1—Prednisone—systemic scleroderma	0.0143	0.0338	CbGbCtD
Carvedilol—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0107	0.0253	CbGbCtD
Carvedilol—SELE—umbilical vein—systemic scleroderma	0.00902	0.0557	CbGeAlD
Carvedilol—CYP3A4—Prednisone—systemic scleroderma	0.00859	0.0202	CbGbCtD
Carvedilol—VCAM1—umbilical vein—systemic scleroderma	0.0083	0.0512	CbGeAlD
Carvedilol—NPPB—artery—systemic scleroderma	0.00749	0.0462	CbGeAlD
Carvedilol—ABCB1—Methotrexate—systemic scleroderma	0.00719	0.0169	CbGbCtD
Carvedilol—CYP2C9—cardial valve—systemic scleroderma	0.00674	0.0416	CbGeAlD
Carvedilol—NPPB—blood vessel—systemic scleroderma	0.00584	0.036	CbGeAlD
Carvedilol—SELE—artery—systemic scleroderma	0.00506	0.0312	CbGeAlD
Carvedilol—VCAM1—artery—systemic scleroderma	0.00466	0.0287	CbGeAlD
Carvedilol—HIF1A—artery—systemic scleroderma	0.00448	0.0276	CbGeAlD
Carvedilol—GJA1—artery—systemic scleroderma	0.00435	0.0268	CbGeAlD
Carvedilol—SELE—endothelium—systemic scleroderma	0.00428	0.0264	CbGeAlD
Carvedilol—SELE—blood vessel—systemic scleroderma	0.00394	0.0243	CbGeAlD
Carvedilol—VCAM1—endothelium—systemic scleroderma	0.00393	0.0243	CbGeAlD
Carvedilol—HIF1A—endothelium—systemic scleroderma	0.00378	0.0233	CbGeAlD
Carvedilol—GJA1—endothelium—systemic scleroderma	0.00367	0.0226	CbGeAlD
Carvedilol—VCAM1—blood vessel—systemic scleroderma	0.00363	0.0224	CbGeAlD
Carvedilol—HIF1A—blood vessel—systemic scleroderma	0.00349	0.0215	CbGeAlD
Carvedilol—GJA1—blood vessel—systemic scleroderma	0.00339	0.0209	CbGeAlD
Carvedilol—NPPB—smooth muscle tissue—systemic scleroderma	0.00274	0.0169	CbGeAlD
Carvedilol—GJA1—Caffeine—Pentoxifylline—systemic scleroderma	0.00244	0.344	CbGdCrCtD
Carvedilol—SELE—connective tissue—systemic scleroderma	0.00202	0.0125	CbGeAlD
Carvedilol—VCAM1—connective tissue—systemic scleroderma	0.00186	0.0115	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—systemic scleroderma	0.00185	0.0114	CbGeAlD
Carvedilol—SELE—skin of body—systemic scleroderma	0.00183	0.0113	CbGeAlD
Carvedilol—HIF1A—connective tissue—systemic scleroderma	0.00179	0.011	CbGeAlD
Carvedilol—GJA1—connective tissue—systemic scleroderma	0.00174	0.0107	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—systemic scleroderma	0.0017	0.0105	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—systemic scleroderma	0.00164	0.0101	CbGeAlD
Carvedilol—HIF1A—skin of body—systemic scleroderma	0.00162	0.00997	CbGeAlD
Carvedilol—ADRB3—connective tissue—systemic scleroderma	0.00159	0.00981	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—systemic scleroderma	0.00159	0.0098	CbGeAlD
Carvedilol—GJA1—skin of body—systemic scleroderma	0.00157	0.00967	CbGeAlD
Carvedilol—SELE—digestive system—systemic scleroderma	0.00146	0.00901	CbGeAlD
Carvedilol—SELE—tendon—systemic scleroderma	0.00139	0.00857	CbGeAlD
Carvedilol—VCAM1—digestive system—systemic scleroderma	0.00134	0.00829	CbGeAlD
Carvedilol—HIF1A—digestive system—systemic scleroderma	0.00129	0.00797	CbGeAlD
Carvedilol—VCAM1—tendon—systemic scleroderma	0.00128	0.00789	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—systemic scleroderma	0.00125	0.00774	CbGeAlD
Carvedilol—GJA1—digestive system—systemic scleroderma	0.00125	0.00773	CbGeAlD
Carvedilol—HIF1A—tendon—systemic scleroderma	0.00123	0.00759	CbGeAlD
Carvedilol—SELE—lung—systemic scleroderma	0.00122	0.00752	CbGeAlD
Carvedilol—GJA1—Enalapril—Captopril—systemic scleroderma	0.00122	0.172	CbGdCrCtD
Carvedilol—GJA1—tendon—systemic scleroderma	0.00119	0.00736	CbGeAlD
Carvedilol—VCAM1—lung—systemic scleroderma	0.00112	0.00692	CbGeAlD
Carvedilol—NDUFC2—digestive system—systemic scleroderma	0.00109	0.00673	CbGeAlD
Carvedilol—HIF1A—lung—systemic scleroderma	0.00108	0.00666	CbGeAlD
Carvedilol—VEGFA—Enalapril—Captopril—systemic scleroderma	0.00107	0.151	CbGdCrCtD
Carvedilol—GJA1—lung—systemic scleroderma	0.00105	0.00646	CbGeAlD
Carvedilol—NDUFC2—tendon—systemic scleroderma	0.00104	0.00641	CbGeAlD
Carvedilol—VEGFA—tendon—systemic scleroderma	0.000942	0.00581	CbGeAlD
Carvedilol—PTGS1—artery—systemic scleroderma	0.000923	0.00569	CbGeAlD
Carvedilol—NDUFC2—lung—systemic scleroderma	0.000911	0.00562	CbGeAlD
Carvedilol—XDH—digestive system—systemic scleroderma	0.000881	0.00544	CbGeAlD
Carvedilol—VEGFA—lung—systemic scleroderma	0.000827	0.0051	CbGeAlD
Carvedilol—PTGS1—endothelium—systemic scleroderma	0.000779	0.00481	CbGeAlD
Carvedilol—PTGS1—blood vessel—systemic scleroderma	0.000719	0.00443	CbGeAlD
Carvedilol—ADRB1—connective tissue—systemic scleroderma	0.00065	0.00401	CbGeAlD
Carvedilol—GJA1—Rimexolone—Mometasone—systemic scleroderma	0.000435	0.0615	CbGdCrCtD
Carvedilol—ABCB1—blood vessel—systemic scleroderma	0.000425	0.00262	CbGeAlD
Carvedilol—GJA1—Enalapril—Lisinopril—systemic scleroderma	0.000401	0.0567	CbGdCrCtD
Carvedilol—ADRB1—lung—systemic scleroderma	0.000392	0.00242	CbGeAlD
Carvedilol—ADRA2A—connective tissue—systemic scleroderma	0.000391	0.00241	CbGeAlD
Carvedilol—CYP1A1—skin of body—systemic scleroderma	0.000379	0.00234	CbGeAlD
Carvedilol—PTGS1—connective tissue—systemic scleroderma	0.000368	0.00227	CbGeAlD
Carvedilol—VEGFA—Enalapril—Lisinopril—systemic scleroderma	0.000353	0.05	CbGdCrCtD
Carvedilol—GJA1—Cortisone acetate—Prednisone—systemic scleroderma	0.000352	0.0498	CbGdCrCtD
Carvedilol—PTGS1—smooth muscle tissue—systemic scleroderma	0.000337	0.00208	CbGeAlD
Carvedilol—ADRA2C—tendon—systemic scleroderma	0.000337	0.00208	CbGeAlD
Carvedilol—PTGS1—skin of body—systemic scleroderma	0.000333	0.00205	CbGeAlD
Carvedilol—CYP1A2—digestive system—systemic scleroderma	0.000307	0.00189	CbGeAlD
Carvedilol—CYP1A1—digestive system—systemic scleroderma	0.000303	0.00187	CbGeAlD
Carvedilol—ADRA2C—lung—systemic scleroderma	0.000296	0.00182	CbGeAlD
Carvedilol—CYP2C9—digestive system—systemic scleroderma	0.000292	0.0018	CbGeAlD
Carvedilol—CYP2E1—digestive system—systemic scleroderma	0.000276	0.0017	CbGeAlD
Carvedilol—ADRA2A—tendon—systemic scleroderma	0.000269	0.00166	CbGeAlD
Carvedilol—PTGS1—digestive system—systemic scleroderma	0.000266	0.00164	CbGeAlD
Carvedilol—CYP2E1—tendon—systemic scleroderma	0.000263	0.00162	CbGeAlD
Carvedilol—CYP1A2—lung—systemic scleroderma	0.000256	0.00158	CbGeAlD
Carvedilol—PTGS1—tendon—systemic scleroderma	0.000253	0.00156	CbGeAlD
Carvedilol—CYP1A1—lung—systemic scleroderma	0.000253	0.00156	CbGeAlD
Carvedilol—GJA1—Rimexolone—Prednisone—systemic scleroderma	0.000237	0.0335	CbGdCrCtD
Carvedilol—ADRA2A—lung—systemic scleroderma	0.000236	0.00146	CbGeAlD
Carvedilol—CYP2E1—lung—systemic scleroderma	0.000231	0.00142	CbGeAlD
Carvedilol—CYP3A4—digestive system—systemic scleroderma	0.000222	0.00137	CbGeAlD
Carvedilol—PTGS1—lung—systemic scleroderma	0.000222	0.00137	CbGeAlD
Carvedilol—CYP2D6—digestive system—systemic scleroderma	0.000219	0.00135	CbGeAlD
Carvedilol—ABCB1—digestive system—systemic scleroderma	0.000157	0.000971	CbGeAlD
Carvedilol—Feeling abnormal—Leflunomide—systemic scleroderma	0.000151	0.000586	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000151	0.000585	CcSEcCtD
Carvedilol—Fatigue—Mycophenolic acid—systemic scleroderma	0.000151	0.000585	CcSEcCtD
Carvedilol—Mood swings—Methotrexate—systemic scleroderma	0.000151	0.000584	CcSEcCtD
Carvedilol—Nausea—Mometasone—systemic scleroderma	0.000151	0.000583	CcSEcCtD
Carvedilol—Anorexia—Lisinopril—systemic scleroderma	0.00015	0.000582	CcSEcCtD
Carvedilol—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00015	0.000581	CcSEcCtD
Carvedilol—Weight increased—Prednisone—systemic scleroderma	0.00015	0.000581	CcSEcCtD
Carvedilol—Pain—Mycophenolic acid—systemic scleroderma	0.00015	0.00058	CcSEcCtD
Carvedilol—Constipation—Mycophenolic acid—systemic scleroderma	0.00015	0.00058	CcSEcCtD
Carvedilol—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00015	0.00058	CcSEcCtD
Carvedilol—Weight decreased—Prednisone—systemic scleroderma	0.000149	0.000577	CcSEcCtD
Carvedilol—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000576	CcSEcCtD
Carvedilol—Hyperglycaemia—Prednisone—systemic scleroderma	0.000148	0.000575	CcSEcCtD
Carvedilol—Cough—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000572	CcSEcCtD
Carvedilol—Hypotension—Lisinopril—systemic scleroderma	0.000147	0.000571	CcSEcCtD
Carvedilol—Dizziness—Captopril—systemic scleroderma	0.000147	0.00057	CcSEcCtD
Carvedilol—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000568	CcSEcCtD
Carvedilol—Depression—Prednisone—systemic scleroderma	0.000146	0.000567	CcSEcCtD
Carvedilol—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000566	CcSEcCtD
Carvedilol—Urticaria—Leflunomide—systemic scleroderma	0.000146	0.000565	CcSEcCtD
Carvedilol—Body temperature increased—Leflunomide—systemic scleroderma	0.000145	0.000562	CcSEcCtD
Carvedilol—Abdominal pain—Leflunomide—systemic scleroderma	0.000145	0.000562	CcSEcCtD
Carvedilol—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000145	0.000561	CcSEcCtD
Carvedilol—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000144	0.000559	CcSEcCtD
Carvedilol—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000558	CcSEcCtD
Carvedilol—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000558	CcSEcCtD
Carvedilol—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000558	CcSEcCtD
Carvedilol—Myocardial infarction—Prednisone—systemic scleroderma	0.000144	0.000558	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000144	0.000557	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000143	0.000555	CcSEcCtD
Carvedilol—Hypersensitivity—Azathioprine—systemic scleroderma	0.000143	0.000555	CcSEcCtD
Carvedilol—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000143	0.000555	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000554	CcSEcCtD
Carvedilol—Insomnia—Lisinopril—systemic scleroderma	0.000143	0.000552	CcSEcCtD
Carvedilol—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000552	CcSEcCtD
Carvedilol—Paraesthesia—Lisinopril—systemic scleroderma	0.000142	0.000548	CcSEcCtD
Carvedilol—Vomiting—Captopril—systemic scleroderma	0.000142	0.000548	CcSEcCtD
Carvedilol—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000546	CcSEcCtD
Carvedilol—Dyspnoea—Lisinopril—systemic scleroderma	0.000141	0.000545	CcSEcCtD
Carvedilol—Rash—Captopril—systemic scleroderma	0.00014	0.000544	CcSEcCtD
Carvedilol—Dermatitis—Captopril—systemic scleroderma	0.00014	0.000543	CcSEcCtD
Carvedilol—Somnolence—Lisinopril—systemic scleroderma	0.00014	0.000543	CcSEcCtD
Carvedilol—Headache—Captopril—systemic scleroderma	0.000139	0.00054	CcSEcCtD
Carvedilol—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000139	0.00054	CcSEcCtD
Carvedilol—Dyspepsia—Lisinopril—systemic scleroderma	0.000139	0.000538	CcSEcCtD
Carvedilol—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000138	0.000536	CcSEcCtD
Carvedilol—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000138	0.000536	CcSEcCtD
Carvedilol—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000535	CcSEcCtD
Carvedilol—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000535	CcSEcCtD
Carvedilol—Infection—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000532	CcSEcCtD
Carvedilol—Decreased appetite—Lisinopril—systemic scleroderma	0.000137	0.000531	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000136	0.000527	CcSEcCtD
Carvedilol—Fatigue—Lisinopril—systemic scleroderma	0.000136	0.000527	CcSEcCtD
Carvedilol—Shock—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000527	CcSEcCtD
Carvedilol—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000524	CcSEcCtD
Carvedilol—Hypersensitivity—Leflunomide—systemic scleroderma	0.000135	0.000524	CcSEcCtD
Carvedilol—Constipation—Lisinopril—systemic scleroderma	0.000135	0.000522	CcSEcCtD
Carvedilol—Pain—Lisinopril—systemic scleroderma	0.000135	0.000522	CcSEcCtD
Carvedilol—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000522	CcSEcCtD
Carvedilol—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00052	CcSEcCtD
Carvedilol—Bradycardia—Prednisone—systemic scleroderma	0.000134	0.00052	CcSEcCtD
Carvedilol—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000517	CcSEcCtD
Carvedilol—Diarrhoea—Azathioprine—systemic scleroderma	0.000133	0.000515	CcSEcCtD
Carvedilol—Haemoglobin—Prednisone—systemic scleroderma	0.000132	0.000513	CcSEcCtD
Carvedilol—Nausea—Captopril—systemic scleroderma	0.000132	0.000512	CcSEcCtD
Carvedilol—Haemorrhage—Prednisone—systemic scleroderma	0.000132	0.000511	CcSEcCtD
Carvedilol—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00051	CcSEcCtD
Carvedilol—Asthenia—Leflunomide—systemic scleroderma	0.000132	0.00051	CcSEcCtD
Carvedilol—ABCB1—lung—systemic scleroderma	0.000131	0.000811	CbGeAlD
Carvedilol—Pancytopenia—Methotrexate—systemic scleroderma	0.000131	0.000506	CcSEcCtD
Carvedilol—Feeling abnormal—Lisinopril—systemic scleroderma	0.00013	0.000503	CcSEcCtD
Carvedilol—Pruritus—Leflunomide—systemic scleroderma	0.00013	0.000503	CcSEcCtD
Carvedilol—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000129	0.0005	CcSEcCtD
Carvedilol—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000129	0.000499	CcSEcCtD
Carvedilol—Dizziness—Azathioprine—systemic scleroderma	0.000128	0.000498	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000128	0.000496	CcSEcCtD
Carvedilol—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000127	0.000491	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000488	CcSEcCtD
Carvedilol—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000126	0.000487	CcSEcCtD
Carvedilol—Asthenia—Mycophenolic acid—systemic scleroderma	0.000126	0.000487	CcSEcCtD
Carvedilol—Diarrhoea—Leflunomide—systemic scleroderma	0.000125	0.000486	CcSEcCtD
Carvedilol—Urticaria—Lisinopril—systemic scleroderma	0.000125	0.000485	CcSEcCtD
Carvedilol—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000484	CcSEcCtD
Carvedilol—Body temperature increased—Lisinopril—systemic scleroderma	0.000125	0.000483	CcSEcCtD
Carvedilol—Abdominal pain—Lisinopril—systemic scleroderma	0.000125	0.000483	CcSEcCtD
Carvedilol—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000481	CcSEcCtD
Carvedilol—Pruritus—Mycophenolic acid—systemic scleroderma	0.000124	0.00048	CcSEcCtD
Carvedilol—Vomiting—Azathioprine—systemic scleroderma	0.000123	0.000479	CcSEcCtD
Carvedilol—Pneumonia—Methotrexate—systemic scleroderma	0.000123	0.000478	CcSEcCtD
Carvedilol—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000477	CcSEcCtD
Carvedilol—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000476	CcSEcCtD
Carvedilol—Rash—Azathioprine—systemic scleroderma	0.000122	0.000475	CcSEcCtD
Carvedilol—Dermatitis—Azathioprine—systemic scleroderma	0.000122	0.000474	CcSEcCtD
Carvedilol—Depression—Methotrexate—systemic scleroderma	0.000122	0.000474	CcSEcCtD
Carvedilol—Headache—Azathioprine—systemic scleroderma	0.000122	0.000472	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000122	0.000471	CcSEcCtD
Carvedilol—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000471	CcSEcCtD
Carvedilol—Dizziness—Leflunomide—systemic scleroderma	0.000121	0.00047	CcSEcCtD
Carvedilol—Renal failure—Methotrexate—systemic scleroderma	0.000121	0.000467	CcSEcCtD
Carvedilol—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000465	CcSEcCtD
Carvedilol—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00012	0.000464	CcSEcCtD
Carvedilol—Angiopathy—Prednisone—systemic scleroderma	0.00012	0.000463	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000462	CcSEcCtD
Carvedilol—Immune system disorder—Prednisone—systemic scleroderma	0.000119	0.000461	CcSEcCtD
Carvedilol—Pain—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000458	CcSEcCtD
Carvedilol—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000458	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—systemic scleroderma	0.000117	0.000453	CcSEcCtD
Carvedilol—Vomiting—Leflunomide—systemic scleroderma	0.000117	0.000452	CcSEcCtD
Carvedilol—Alopecia—Prednisone—systemic scleroderma	0.000116	0.000451	CcSEcCtD
Carvedilol—Hypersensitivity—Lisinopril—systemic scleroderma	0.000116	0.00045	CcSEcCtD
Carvedilol—Dizziness—Mycophenolic acid—systemic scleroderma	0.000116	0.000448	CcSEcCtD
Carvedilol—Rash—Leflunomide—systemic scleroderma	0.000116	0.000448	CcSEcCtD
Carvedilol—Dermatitis—Leflunomide—systemic scleroderma	0.000116	0.000448	CcSEcCtD
Carvedilol—Nausea—Azathioprine—systemic scleroderma	0.000115	0.000447	CcSEcCtD
Carvedilol—Headache—Leflunomide—systemic scleroderma	0.000115	0.000445	CcSEcCtD
Carvedilol—Malnutrition—Prednisone—systemic scleroderma	0.000115	0.000445	CcSEcCtD
Carvedilol—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000441	CcSEcCtD
Carvedilol—Asthenia—Lisinopril—systemic scleroderma	0.000113	0.000438	CcSEcCtD
Carvedilol—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000438	CcSEcCtD
Carvedilol—Pruritus—Lisinopril—systemic scleroderma	0.000112	0.000432	CcSEcCtD
Carvedilol—Vomiting—Mycophenolic acid—systemic scleroderma	0.000111	0.000431	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—systemic scleroderma	0.000111	0.000429	CcSEcCtD
Carvedilol—Rash—Mycophenolic acid—systemic scleroderma	0.00011	0.000428	CcSEcCtD
Carvedilol—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00011	0.000427	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—systemic scleroderma	0.00011	0.000427	CcSEcCtD
Carvedilol—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000425	CcSEcCtD
Carvedilol—Headache—Mycophenolic acid—systemic scleroderma	0.00011	0.000425	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—systemic scleroderma	0.000109	0.000424	CcSEcCtD
Carvedilol—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000423	CcSEcCtD
Carvedilol—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000423	CcSEcCtD
Carvedilol—Nausea—Leflunomide—systemic scleroderma	0.000109	0.000422	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000109	0.000421	CcSEcCtD
Carvedilol—Vision blurred—Prednisone—systemic scleroderma	0.000108	0.000419	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—systemic scleroderma	0.000108	0.000418	CcSEcCtD
Carvedilol—Diarrhoea—Lisinopril—systemic scleroderma	0.000108	0.000418	CcSEcCtD
Carvedilol—Ill-defined disorder—Prednisone—systemic scleroderma	0.000106	0.000412	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—systemic scleroderma	0.000106	0.000411	CcSEcCtD
Carvedilol—Anaemia—Prednisone—systemic scleroderma	0.000106	0.000411	CcSEcCtD
Carvedilol—Angioedema—Prednisone—systemic scleroderma	0.000105	0.000406	CcSEcCtD
Carvedilol—Dizziness—Lisinopril—systemic scleroderma	0.000104	0.000404	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—systemic scleroderma	0.000104	0.000403	CcSEcCtD
Carvedilol—Nausea—Mycophenolic acid—systemic scleroderma	0.000104	0.000403	CcSEcCtD
Carvedilol—Malaise—Prednisone—systemic scleroderma	0.000103	0.000401	CcSEcCtD
Carvedilol—Vertigo—Prednisone—systemic scleroderma	0.000103	0.000399	CcSEcCtD
Carvedilol—Syncope—Prednisone—systemic scleroderma	0.000103	0.000399	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—systemic scleroderma	0.000103	0.000398	CcSEcCtD
Carvedilol—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000394	CcSEcCtD
Carvedilol—Loss of consciousness—Prednisone—systemic scleroderma	0.000101	0.000391	CcSEcCtD
Carvedilol—Vomiting—Lisinopril—systemic scleroderma	0.0001	0.000388	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—systemic scleroderma	9.99e-05	0.000387	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—systemic scleroderma	9.95e-05	0.000385	CcSEcCtD
Carvedilol—Rash—Lisinopril—systemic scleroderma	9.94e-05	0.000385	CcSEcCtD
Carvedilol—Convulsion—Prednisone—systemic scleroderma	9.94e-05	0.000385	CcSEcCtD
Carvedilol—Dermatitis—Lisinopril—systemic scleroderma	9.93e-05	0.000385	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—systemic scleroderma	9.92e-05	0.000385	CcSEcCtD
Carvedilol—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.91e-05	0.000384	CcSEcCtD
Carvedilol—Hypertension—Prednisone—systemic scleroderma	9.9e-05	0.000384	CcSEcCtD
Carvedilol—Headache—Lisinopril—systemic scleroderma	9.87e-05	0.000383	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Mometasone—systemic scleroderma	9.84e-05	0.0139	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Mometasone—systemic scleroderma	9.84e-05	0.0139	CbGdCrCtD
Carvedilol—Pruritus—Mycophenolate mofetil—systemic scleroderma	9.77e-05	0.000379	CcSEcCtD
Carvedilol—Arthralgia—Prednisone—systemic scleroderma	9.76e-05	0.000378	CcSEcCtD
Carvedilol—Myalgia—Prednisone—systemic scleroderma	9.76e-05	0.000378	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—systemic scleroderma	9.73e-05	0.000377	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	9.7e-05	0.000376	CcSEcCtD
Carvedilol—Discomfort—Prednisone—systemic scleroderma	9.65e-05	0.000374	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—systemic scleroderma	9.59e-05	0.000371	CcSEcCtD
Carvedilol—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	9.45e-05	0.000366	CcSEcCtD
Carvedilol—Nausea—Lisinopril—systemic scleroderma	9.36e-05	0.000363	CcSEcCtD
Carvedilol—Anaphylactic shock—Prednisone—systemic scleroderma	9.36e-05	0.000363	CcSEcCtD
Carvedilol—Oedema—Prednisone—systemic scleroderma	9.36e-05	0.000363	CcSEcCtD
Carvedilol—Infection—Prednisone—systemic scleroderma	9.3e-05	0.00036	CcSEcCtD
Carvedilol—Back pain—Methotrexate—systemic scleroderma	9.27e-05	0.000359	CcSEcCtD
Carvedilol—Shock—Prednisone—systemic scleroderma	9.21e-05	0.000357	CcSEcCtD
Carvedilol—Tachycardia—Prednisone—systemic scleroderma	9.14e-05	0.000354	CcSEcCtD
Carvedilol—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.000354	CcSEcCtD
Carvedilol—Skin disorder—Prednisone—systemic scleroderma	9.09e-05	0.000352	CcSEcCtD
Carvedilol—Hyperhidrosis—Prednisone—systemic scleroderma	9.05e-05	0.000351	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—systemic scleroderma	9.03e-05	0.00035	CcSEcCtD
Carvedilol—Anorexia—Prednisone—systemic scleroderma	8.92e-05	0.000346	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—systemic scleroderma	8.89e-05	0.000345	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—systemic scleroderma	8.86e-05	0.000343	CcSEcCtD
Carvedilol—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.78e-05	0.00034	CcSEcCtD
Carvedilol—Rash—Mycophenolate mofetil—systemic scleroderma	8.71e-05	0.000337	CcSEcCtD
Carvedilol—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.7e-05	0.000337	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Mometasone—systemic scleroderma	8.68e-05	0.0123	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Mometasone—systemic scleroderma	8.68e-05	0.0123	CbGdCrCtD
Carvedilol—Headache—Mycophenolate mofetil—systemic scleroderma	8.65e-05	0.000335	CcSEcCtD
Carvedilol—Malaise—Methotrexate—systemic scleroderma	8.64e-05	0.000335	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—systemic scleroderma	8.61e-05	0.000334	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—systemic scleroderma	8.58e-05	0.000333	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Prednisone—systemic scleroderma	8.53e-05	0.000331	CcSEcCtD
Carvedilol—Insomnia—Prednisone—systemic scleroderma	8.47e-05	0.000328	CcSEcCtD
Carvedilol—Paraesthesia—Prednisone—systemic scleroderma	8.41e-05	0.000326	CcSEcCtD
Carvedilol—Cough—Methotrexate—systemic scleroderma	8.36e-05	0.000324	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—systemic scleroderma	8.3e-05	0.000322	CcSEcCtD
Carvedilol—Dyspepsia—Prednisone—systemic scleroderma	8.24e-05	0.000319	CcSEcCtD
Carvedilol—Nausea—Mycophenolate mofetil—systemic scleroderma	8.2e-05	0.000318	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—systemic scleroderma	8.16e-05	0.000316	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—systemic scleroderma	8.16e-05	0.000316	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—systemic scleroderma	8.16e-05	0.000316	CcSEcCtD
Carvedilol—Decreased appetite—Prednisone—systemic scleroderma	8.14e-05	0.000315	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	8.1e-05	0.000314	CcSEcCtD
Carvedilol—Fatigue—Prednisone—systemic scleroderma	8.07e-05	0.000313	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—systemic scleroderma	8.06e-05	0.000312	CcSEcCtD
Carvedilol—Constipation—Prednisone—systemic scleroderma	8e-05	0.00031	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—systemic scleroderma	7.89e-05	0.000306	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—systemic scleroderma	7.82e-05	0.000303	CcSEcCtD
Carvedilol—Infection—Methotrexate—systemic scleroderma	7.77e-05	0.000301	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisone—systemic scleroderma	7.71e-05	0.000299	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—systemic scleroderma	7.66e-05	0.000297	CcSEcCtD
Carvedilol—Gastrointestinal pain—Prednisone—systemic scleroderma	7.65e-05	0.000297	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—systemic scleroderma	7.6e-05	0.000294	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—systemic scleroderma	7.56e-05	0.000293	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—systemic scleroderma	7.46e-05	0.000289	CcSEcCtD
Carvedilol—Urticaria—Prednisone—systemic scleroderma	7.44e-05	0.000288	CcSEcCtD
Carvedilol—Abdominal pain—Prednisone—systemic scleroderma	7.4e-05	0.000287	CcSEcCtD
Carvedilol—Body temperature increased—Prednisone—systemic scleroderma	7.4e-05	0.000287	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—systemic scleroderma	7.31e-05	0.000283	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.13e-05	0.000276	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—systemic scleroderma	7.08e-05	0.000274	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—systemic scleroderma	7.02e-05	0.000272	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—systemic scleroderma	6.97e-05	0.00027	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—systemic scleroderma	6.95e-05	0.00027	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisone—systemic scleroderma	6.9e-05	0.000267	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—systemic scleroderma	6.89e-05	0.000267	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—systemic scleroderma	6.8e-05	0.000264	CcSEcCtD
Carvedilol—ADRA2C—Hemostasis—CSK—systemic scleroderma	6.77e-05	0.000456	CbGpPWpGaD
Carvedilol—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.75e-05	0.000262	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—systemic scleroderma	6.74e-05	0.000261	CcSEcCtD
Carvedilol—Asthenia—Prednisone—systemic scleroderma	6.72e-05	0.00026	CcSEcCtD
Carvedilol—Pain—Methotrexate—systemic scleroderma	6.69e-05	0.000259	CcSEcCtD
Carvedilol—Pruritus—Prednisone—systemic scleroderma	6.62e-05	0.000257	CcSEcCtD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	6.61e-05	0.000446	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	6.58e-05	0.000444	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—SELP—systemic scleroderma	6.46e-05	0.000436	CbGpPWpGaD
Carvedilol—Feeling abnormal—Methotrexate—systemic scleroderma	6.45e-05	0.00025	CcSEcCtD
Carvedilol—Diarrhoea—Prednisone—systemic scleroderma	6.4e-05	0.000248	CcSEcCtD
Carvedilol—VEGFA—Axon guidance—MMP2—systemic scleroderma	6.4e-05	0.000432	CbGpPWpGaD
Carvedilol—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.4e-05	0.000248	CcSEcCtD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.37e-05	0.000429	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—ITGAM—systemic scleroderma	6.36e-05	0.000429	CbGpPWpGaD
Carvedilol—Urticaria—Methotrexate—systemic scleroderma	6.21e-05	0.000241	CcSEcCtD
Carvedilol—Dizziness—Prednisone—systemic scleroderma	6.19e-05	0.00024	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—systemic scleroderma	6.18e-05	0.00024	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—systemic scleroderma	6.18e-05	0.00024	CcSEcCtD
Carvedilol—XDH—Metabolism—HSPG2—systemic scleroderma	6.06e-05	0.000408	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.05e-05	0.000408	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—RHOB—systemic scleroderma	6.03e-05	0.000407	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	6.02e-05	0.000406	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	6e-05	0.000405	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	5.96e-05	0.000402	CbGpPWpGaD
Carvedilol—Vomiting—Prednisone—systemic scleroderma	5.95e-05	0.000231	CcSEcCtD
Carvedilol—ADRB3—Signaling Pathways—SMAD7—systemic scleroderma	5.93e-05	0.0004	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—SMAD7—systemic scleroderma	5.91e-05	0.000399	CbGpPWpGaD
Carvedilol—Rash—Prednisone—systemic scleroderma	5.9e-05	0.000229	CcSEcCtD
Carvedilol—Dermatitis—Prednisone—systemic scleroderma	5.9e-05	0.000229	CcSEcCtD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	5.89e-05	0.000397	CbGpPWpGaD
Carvedilol—Headache—Prednisone—systemic scleroderma	5.86e-05	0.000227	CcSEcCtD
Carvedilol—VEGFA—Hemostasis—MMP1—systemic scleroderma	5.79e-05	0.000391	CbGpPWpGaD
Carvedilol—Hypersensitivity—Methotrexate—systemic scleroderma	5.76e-05	0.000223	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—systemic scleroderma	5.61e-05	0.000218	CcSEcCtD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	5.57e-05	0.000376	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—RHOB—systemic scleroderma	5.57e-05	0.000376	CbGpPWpGaD
Carvedilol—Nausea—Prednisone—systemic scleroderma	5.56e-05	0.000215	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—systemic scleroderma	5.53e-05	0.000215	CcSEcCtD
Carvedilol—ADRA2A—Hemostasis—CSK—systemic scleroderma	5.5e-05	0.000371	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	5.48e-05	0.00037	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EDN1—systemic scleroderma	5.41e-05	0.000365	CbGpPWpGaD
Carvedilol—VEGFA—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	5.39e-05	0.000363	CbGpPWpGaD
Carvedilol—GJA1—Dexamethasone—Prednisone—systemic scleroderma	5.37e-05	0.00758	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Prednisone—systemic scleroderma	5.37e-05	0.00758	CbGdCrCtD
Carvedilol—Diarrhoea—Methotrexate—systemic scleroderma	5.35e-05	0.000207	CcSEcCtD
Carvedilol—ADRB3—GPCR ligand binding—CCL2—systemic scleroderma	5.28e-05	0.000356	CbGpPWpGaD
Carvedilol—Dizziness—Methotrexate—systemic scleroderma	5.17e-05	0.0002	CcSEcCtD
Carvedilol—ADRA2A—Hemostasis—ITGAM—systemic scleroderma	5.17e-05	0.000349	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—NOS3—systemic scleroderma	5.12e-05	0.000345	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—RHOB—systemic scleroderma	5.07e-05	0.000342	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—RHOB—systemic scleroderma	5.06e-05	0.000341	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—EDN1—systemic scleroderma	5.03e-05	0.000339	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—RHOB—systemic scleroderma	5.03e-05	0.000339	CbGpPWpGaD
Carvedilol—Vomiting—Methotrexate—systemic scleroderma	4.97e-05	0.000193	CcSEcCtD
Carvedilol—ADRB2—GPCR downstream signaling—RHOB—systemic scleroderma	4.96e-05	0.000335	CbGpPWpGaD
Carvedilol—Rash—Methotrexate—systemic scleroderma	4.93e-05	0.000191	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—systemic scleroderma	4.93e-05	0.000191	CcSEcCtD
Carvedilol—Headache—Methotrexate—systemic scleroderma	4.9e-05	0.00019	CcSEcCtD
Carvedilol—VCAM1—Immune System—IL1B—systemic scleroderma	4.9e-05	0.00033	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	4.88e-05	0.000329	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	4.87e-05	0.000329	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.82e-05	0.000325	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—MMP9—systemic scleroderma	4.81e-05	0.000325	CbGpPWpGaD
Carvedilol—VEGFA—Betamethasone—Prednisone—systemic scleroderma	4.73e-05	0.00668	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Prednisone—systemic scleroderma	4.73e-05	0.00668	CbGdCrCtD
Carvedilol—HIF1A—Disease—NOS3—systemic scleroderma	4.71e-05	0.000318	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—RHOB—systemic scleroderma	4.69e-05	0.000317	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.67e-05	0.000315	CbGpPWpGaD
Carvedilol—Nausea—Methotrexate—systemic scleroderma	4.65e-05	0.00018	CcSEcCtD
Carvedilol—ADRA1B—GPCR downstream signaling—RHOB—systemic scleroderma	4.62e-05	0.000312	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—RHOB—systemic scleroderma	4.61e-05	0.000311	CbGpPWpGaD
Carvedilol—XDH—Metabolism—CTGF—systemic scleroderma	4.59e-05	0.00031	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RHOB—systemic scleroderma	4.58e-05	0.000309	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—EDN1—systemic scleroderma	4.58e-05	0.000309	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RHOB—systemic scleroderma	4.57e-05	0.000309	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP2—systemic scleroderma	4.57e-05	0.000308	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—RHOB—systemic scleroderma	4.56e-05	0.000308	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—EDN1—systemic scleroderma	4.54e-05	0.000306	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	4.52e-05	0.000305	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.52e-05	0.000305	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—RHOB—systemic scleroderma	4.51e-05	0.000304	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.49e-05	0.000303	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—EDN1—systemic scleroderma	4.48e-05	0.000302	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—EDN1—systemic scleroderma	4.36e-05	0.000294	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HSPG2—systemic scleroderma	4.32e-05	0.000292	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HSPG2—systemic scleroderma	4.31e-05	0.000291	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—RHOB—systemic scleroderma	4.26e-05	0.000288	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—EDN1—systemic scleroderma	4.24e-05	0.000286	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—NOS3—systemic scleroderma	4.2e-05	0.000283	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—RHOB—systemic scleroderma	4.2e-05	0.000283	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CSK—systemic scleroderma	4.18e-05	0.000282	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—EDN1—systemic scleroderma	4.17e-05	0.000282	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CSK—systemic scleroderma	4.17e-05	0.000281	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.11e-05	0.000278	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—RHOB—systemic scleroderma	4.1e-05	0.000277	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.08e-05	0.000275	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.02e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EDN1—systemic scleroderma	3.96e-05	0.000267	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SMAD7—systemic scleroderma	3.86e-05	0.00026	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—RHOB—systemic scleroderma	3.81e-05	0.000257	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.81e-05	0.000257	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.79e-05	0.000256	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.75e-05	0.000253	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—RHOB—systemic scleroderma	3.73e-05	0.000251	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—EDN1—systemic scleroderma	3.71e-05	0.00025	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CCL2—systemic scleroderma	3.7e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SMAD7—systemic scleroderma	3.52e-05	0.000237	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SMAD7—systemic scleroderma	3.49e-05	0.000235	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—RHOB—systemic scleroderma	3.46e-05	0.000234	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—EDN1—systemic scleroderma	3.45e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SMAD7—systemic scleroderma	3.44e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—CCL2—systemic scleroderma	3.44e-05	0.000232	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP9—systemic scleroderma	3.43e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—MMP1—systemic scleroderma	3.41e-05	0.00023	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.4e-05	0.000229	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.35e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.33e-05	0.000225	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NOS3—systemic scleroderma	3.3e-05	0.000222	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SMAD7—systemic scleroderma	3.26e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SMAD7—systemic scleroderma	3.2e-05	0.000216	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—MMP1—systemic scleroderma	3.19e-05	0.000215	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.17e-05	0.000214	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CCL2—systemic scleroderma	3.13e-05	0.000211	CbGpPWpGaD
Carvedilol—HIF1A—Disease—TGFB1—systemic scleroderma	3.11e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CCL2—systemic scleroderma	3.1e-05	0.000209	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.09e-05	0.000209	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CCL2—systemic scleroderma	3.06e-05	0.000207	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RHOB—systemic scleroderma	2.99e-05	0.000201	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.96e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CCL2—systemic scleroderma	2.9e-05	0.000196	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.86e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CCL2—systemic scleroderma	2.85e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMAD7—systemic scleroderma	2.85e-05	0.000192	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—EDN1—systemic scleroderma	2.84e-05	0.000192	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—HSPG2—systemic scleroderma	2.84e-05	0.000192	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—HSPG2—systemic scleroderma	2.84e-05	0.000191	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TGFB1—systemic scleroderma	2.83e-05	0.000191	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HSPG2—systemic scleroderma	2.82e-05	0.00019	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TGFB1—systemic scleroderma	2.78e-05	0.000187	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RHOB—systemic scleroderma	2.72e-05	0.000184	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CSK—systemic scleroderma	2.72e-05	0.000184	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CCL2—systemic scleroderma	2.71e-05	0.000183	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RHOB—systemic scleroderma	2.7e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RHOB—systemic scleroderma	2.66e-05	0.00018	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MMP9—systemic scleroderma	2.65e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMAD7—systemic scleroderma	2.64e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—EDN1—systemic scleroderma	2.59e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—MMP1—systemic scleroderma	2.59e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EDN1—systemic scleroderma	2.58e-05	0.000174	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—EDN1—systemic scleroderma	2.57e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HSPG2—systemic scleroderma	2.57e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HSPG2—systemic scleroderma	2.54e-05	0.000172	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.54e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CCL2—systemic scleroderma	2.53e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—EDN1—systemic scleroderma	2.53e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RHOB—systemic scleroderma	2.52e-05	0.00017	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HSPG2—systemic scleroderma	2.51e-05	0.000169	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RHOB—systemic scleroderma	2.48e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CSK—systemic scleroderma	2.48e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NOS3—systemic scleroderma	2.47e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CSK—systemic scleroderma	2.46e-05	0.000166	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CSK—systemic scleroderma	2.42e-05	0.000164	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.41e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—EDN1—systemic scleroderma	2.4e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HSPG2—systemic scleroderma	2.38e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—EDN1—systemic scleroderma	2.36e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CCL2—systemic scleroderma	2.36e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EDN1—systemic scleroderma	2.35e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EDN1—systemic scleroderma	2.34e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HSPG2—systemic scleroderma	2.34e-05	0.000158	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EDN1—systemic scleroderma	2.34e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EDN1—systemic scleroderma	2.33e-05	0.000157	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NOS3—systemic scleroderma	2.31e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—HSPG2—systemic scleroderma	2.31e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EDN1—systemic scleroderma	2.3e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CSK—systemic scleroderma	2.29e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CSK—systemic scleroderma	2.26e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RHOB—systemic scleroderma	2.2e-05	0.000149	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TGFB1—systemic scleroderma	2.18e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EDN1—systemic scleroderma	2.18e-05	0.000147	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.17e-05	0.000146	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CTGF—systemic scleroderma	2.15e-05	0.000145	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CTGF—systemic scleroderma	2.15e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EDN1—systemic scleroderma	2.14e-05	0.000145	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—HSPG2—systemic scleroderma	2.12e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—EDN1—systemic scleroderma	2.1e-05	0.000141	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HSPG2—systemic scleroderma	2.08e-05	0.00014	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RHOB—systemic scleroderma	2.05e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CSK—systemic scleroderma	2.01e-05	0.000135	CbGpPWpGaD
Carvedilol—XDH—Metabolism—NOS3—systemic scleroderma	2e-05	0.000135	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—HSPG2—systemic scleroderma	2e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—EDN1—systemic scleroderma	1.95e-05	0.000131	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HSPG2—systemic scleroderma	1.93e-05	0.00013	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EDN1—systemic scleroderma	1.9e-05	0.000128	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NOS3—systemic scleroderma	1.88e-05	0.000127	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.87e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CSK—systemic scleroderma	1.86e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EDN1—systemic scleroderma	1.77e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CCL2—systemic scleroderma	1.76e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CTGF—systemic scleroderma	1.75e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TGFB1—systemic scleroderma	1.64e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CCL2—systemic scleroderma	1.61e-05	0.000108	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CTGF—systemic scleroderma	1.61e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCL2—systemic scleroderma	1.6e-05	0.000108	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCL2—systemic scleroderma	1.6e-05	0.000108	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.6e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CCL2—systemic scleroderma	1.59e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CCL2—systemic scleroderma	1.57e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TGFB1—systemic scleroderma	1.53e-05	0.000103	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EDN1—systemic scleroderma	1.52e-05	0.000103	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.51e-05	0.000102	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.5e-05	0.000101	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.49e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCL2—systemic scleroderma	1.49e-05	0.0001	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCL2—systemic scleroderma	1.46e-05	9.88e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NOS3—systemic scleroderma	1.43e-05	9.62e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NOS3—systemic scleroderma	1.42e-05	9.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EDN1—systemic scleroderma	1.39e-05	9.37e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EDN1—systemic scleroderma	1.38e-05	9.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EDN1—systemic scleroderma	1.36e-05	9.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCL2—systemic scleroderma	1.3e-05	8.78e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EDN1—systemic scleroderma	1.29e-05	8.68e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.27e-05	8.59e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EDN1—systemic scleroderma	1.27e-05	8.54e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TGFB1—systemic scleroderma	1.24e-05	8.37e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CTGF—systemic scleroderma	1.21e-05	8.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCL2—systemic scleroderma	1.21e-05	8.15e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—systemic scleroderma	1.14e-05	7.72e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—systemic scleroderma	1.14e-05	7.7e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.14e-05	7.69e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.13e-05	7.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EDN1—systemic scleroderma	1.12e-05	7.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EDN1—systemic scleroderma	1.04e-05	7.05e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCL2—systemic scleroderma	1.04e-05	7.03e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HSPG2—systemic scleroderma	9.83e-06	6.63e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CTGF—systemic scleroderma	9.65e-06	6.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL2—systemic scleroderma	9.5e-06	6.41e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TGFB1—systemic scleroderma	9.43e-06	6.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL2—systemic scleroderma	9.41e-06	6.35e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TGFB1—systemic scleroderma	9.41e-06	6.35e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—NOS3—systemic scleroderma	9.37e-06	6.32e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—NOS3—systemic scleroderma	9.35e-06	6.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL2—systemic scleroderma	9.29e-06	6.27e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOS3—systemic scleroderma	9.29e-06	6.27e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL2—systemic scleroderma	8.79e-06	5.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL2—systemic scleroderma	8.65e-06	5.84e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOS3—systemic scleroderma	8.47e-06	5.71e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOS3—systemic scleroderma	8.39e-06	5.66e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOS3—systemic scleroderma	8.28e-06	5.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOS3—systemic scleroderma	7.84e-06	5.29e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOS3—systemic scleroderma	7.71e-06	5.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL2—systemic scleroderma	7.68e-06	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—NOS3—systemic scleroderma	7.61e-06	5.13e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—systemic scleroderma	7.45e-06	5.03e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CTGF—systemic scleroderma	7.45e-06	5.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL2—systemic scleroderma	7.14e-06	4.82e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—NOS3—systemic scleroderma	6.99e-06	4.71e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOS3—systemic scleroderma	6.85e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—systemic scleroderma	6.79e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—systemic scleroderma	6.73e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—systemic scleroderma	6.64e-06	4.48e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—NOS3—systemic scleroderma	6.59e-06	4.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—systemic scleroderma	6.36e-06	4.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—systemic scleroderma	6.29e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—systemic scleroderma	6.19e-06	4.17e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—systemic scleroderma	6.14e-06	4.14e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—systemic scleroderma	5.6e-06	3.78e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—systemic scleroderma	5.55e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—systemic scleroderma	5.5e-06	3.71e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—systemic scleroderma	5.48e-06	3.69e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—systemic scleroderma	5.26e-06	3.55e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—systemic scleroderma	5.18e-06	3.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—systemic scleroderma	5.11e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—systemic scleroderma	5.1e-06	3.44e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—systemic scleroderma	4.96e-06	3.35e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—systemic scleroderma	4.92e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—systemic scleroderma	4.53e-06	3.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—systemic scleroderma	4.21e-06	2.84e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—systemic scleroderma	4.2e-06	2.83e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.24e-06	2.19e-05	CbGpPWpGaD
